Press Releases

10/13/2011
Synageva BioPharma And Trimeris Announce Special Meetings Of Stockholders To Approve Merger

9/28/2011
Synageva BioPharma Expands International Clinical Trial For Infants With Lysosomal Acid Lipase Deficiency, A Lysosomal Storage Disorder

9/7/2011
Synageva BioPharma To Present At Morgan Stanley Global Healthcare Conference

9/6/2011
Synageva BioPharma Announces Appointment Of Leading Clinician And Rare Disease Pioneer As Senior Vice President Of Product Development

9/1/2011
Synageva BioPharma Corp Enters Development Collaboration With Mitsubishi Tanabe Pharma Corporation

7/18/2011
Synageva BioPharma And Trimeris Announce Filing Of S-4 Registration Statement

6/23/2011
Synageva BioPharma Receives FDA Fast Track Designation For SBC-102 For Lysosomal Acid Lipase Deficiency

6/13/2011
Synageva BioPharma And Trimeris Announce Merger Agreement

6/8/2011
Synageva BioPharma Presents At The Jefferies 2011 Global Healthcare Conference

5/26/2011
Synageva BioPharma Presents Data On SBC-102 At Annual Meeting Of The European Society For Paediatric Gastroenterology, Hepatology and Nutrition

4/1/2011
Synageva Biopharma Presents Data at The International Liver Congress™ 2011 on Lysosomal Acid Lipase (LAL) Deficiency

3/21/2011
Synageva BioPharma Announces Additional $25 Million Funding to Support Rare Disease Product Development

2/28/2011
Synageva BioPharma Announces Support of Annual Rare Disease Day - Initiates First Ever Clinical Program for Lysosomal Acid Lipase Deficiency

2/1/2011
Synageva BioPharma to Present Preclinical Data on Lysosomal Acid Lipase (LAL) Deficiency (Also Known as Wolman Disease and Cholesteryl Ester Storage Disease) at the Lysosomal Disease Network's 2011 World Symposium

1/5/2011
Synageva BioPharma Corp and to-BBB to Collaborate on Brain Drug Delivery for Rare Diseases

12/20/2010
Synageva BioPharma to Present at The 29th Annual J.P. Morgan Healthcare Conference

11/9/2010
Synageva BioPharma Receives European Orphan Medicinal Product Designation for SBC-102 for Lysosomal Acid Lipase Deficiency

11/4/2010
Synageva BioPharma Presents Data at The American Society of Human Genetics On SBC-102 For Lysosomal Acid Lipase Deficiency

11/3/2010
US Government Awards More Than $2 Million to Synageva BioPharma

9/15/2010
Synageva BioPharma Expands into New Office and Laboratory Facilities to Support Advancement of Its Rare Disease Pipeline

7/7/2010
Synageva BioPharma Receives Orphan Drug Designation for SBC-102 for Lysosomal Acid Lipase Deficiency

5/4/2010
Synageva BioPharma Files for Orphan Drug Designation for SBC-102, Being Developed to be the First Enzyme Replacement Therapy to Treat Lysosomal Acid Lipase Deficiency - A Progressive, Often Fatal Disease

10/20/2009
Synageva BioPharma Announces Completion of $45 Million Financing With New $12 Million Investment, Addition of New Leaf Venture Partners to Investor Group, and Expansion of Senior Leadership Team

7/1/2009
Morphotek®, Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corp. to Develop Potential Treatments for Cancer and Infectious Disease

5/5/2009
Synageva Biopharma Adds Two New Investors and Announces Additional Funding

4/15/2009
Synageva Biopharma Announces $30 Million Equity Financing

10/10/2008
Synageva Biopharma Appoints Leading Clinician and Industry Executive, Dr. Mark Goldberg, to its Board of Directors

9/4/2008
Synageva Biopharma Appoints Sanj K. Patel President and Chief Executive Officer and Opens New Corporate Headquarters